Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
10 min read
Multiple endocrine neoplasia type 2B Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Multiple endocrine neoplasia type 2B strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Latest Hotspot
10 min read
Pituitary gigantism Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Pituitary gigantism indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Carney complex Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Carney complex indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Multiple endocrine neoplasia type 2A Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Multiple endocrine neoplasia type 2A strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Latest Hotspot
10 min read
Multiple endocrine neoplasia type 1 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Multiple endocrine neoplasia type 1 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Familial male-limited precocious puberty Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Familial male-limited precocious puberty strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Latest Hotspot
10 min read
Aromatase excess syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Aromatase excess syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
P450 oxidoreductase deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 P450 oxidoreductase deficiency strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
3-beta-hydroxysteroid dehydrogenase deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 3-beta-hydroxysteroid dehydrogenase deficiency strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Latest Hotspot
10 min read
Aromatase deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Aromatase deficiency strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
17-alpha-hydroxylase deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 17-alpha-hydroxylase deficiency strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
11-beta-hydroxylase deficiency Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 11-beta-hydroxylase deficiency strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.